<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Drugs Acting on Blood - Pharmacology and Pharmacotherapeutics</title>
    
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">
    
    <link rel="stylesheet" href="../styles/main.css">
    
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams'
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <a href="#main-content" class="skip-link">Skip to main content</a>
    
    <div class="reading-progress-container">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <!-- Floating Table of Contents -->
    <div class="floating-toc" id="floating-toc">
        <div class="floating-toc-header">
            <span>üìë</span>
            <span>Contents</span>
        </div>
        <ul class="floating-toc-list">
            <!-- JS will populate this -->
        </ul>
    </div>

    <div class="page-wrapper">
        <div class="container">
            <article class="document-article">
                <header class="document-header">
                    <div class="header-badge">
                        <span>ü©∏</span>
                        <span>Section VIII</span>
                    </div>
                    <h1 class="document-title">Drugs Acting on Blood and Blood Forming Organs</h1>
                    <div class="title-meta">
                        <div class="meta-item">
                            <span>üìö</span>
                            <span>Coagulation, Anemia & Growth Factors</span>
                        </div>
                        <div class="meta-item">
                            <span>‚è±Ô∏è</span>
                            <span>60 min read</span>
                        </div>
                    </div>
                </header>

                <main id="main-content" class="content-wrapper">
                    <!-- START: Chapter 33 -->
                    <section class="content-section" id="chapter-33">
                        <div class="section-header">
                            <div class="section-number">33</div>
                            <h2 class="section-title">
                                <span class="title-icon">üíâ</span>
                                Drugs and Blood Coagulation
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Drugs are often used in therapeutics to prevent blood coagulation and to arrest blood loss. They act on various stages of coagulation: platelet aggregation, fibrin formation, or fibrinolysis.</p>

                            <h3>Hemostasis and Thrombosis</h3>
                            <p>Hemostasis involves vasoconstriction, platelet adhesion/aggregation (primary hemostatic plug), and fibrin formation (coagulation cascade). <strong>Arterial thrombi</strong> (white thrombi) are platelet-rich, while <strong>venous thrombi</strong> (red thrombi) are fibrin-rich.</p>

                            <h3>Antiplatelet Agents</h3>
                            <p>These drugs inhibit platelet aggregation and are primarily used to prevent arterial thrombosis.</p>

                            <h4>1. Aspirin</h4>
                            <p><strong>Mechanism:</strong> Irreversibly acetylates COX-1, inhibiting Thromboxane A2 (TXA2) synthesis for the life of the platelet (7-10 days). Low doses (75-150 mg/day) selectively inhibit platelet COX-1 while sparing endothelial Prostacyclin (PGI2) synthesis to some extent.</p>
                            <p><strong>Uses:</strong> Secondary prevention of MI and stroke; unstable angina; post-angioplasty.</p>

                            <h4>2. ADP Receptor Antagonists</h4>
                            <p><strong>Clopidogrel, Ticlopidine, Prasugrel, Ticagrelor.</strong></p>
                            <ul>
                                <li><strong>Clopidogrel:</strong> Prodrug. Irreversibly blocks P2Y12 ADP receptors. Used in aspirin-intolerant patients and combined with aspirin in ACS/stenting. <strong>Adverse effects:</strong> Bleeding, interactions (activation inhibited by PPIs like omeprazole).</li>
                                <li><strong>Ticagrelor:</strong> Reversible P2Y12 inhibitor. Faster onset.</li>
                            </ul>

                            <h4>3. Glycoprotein IIb/IIIa Antagonists</h4>
                            <p><strong>Abciximab, Tirofiban, Eptifibatide.</strong> Block the final common pathway of platelet aggregation (fibrinogen binding). Used IV in high-risk PCI/ACS.</p>

                            <h4>4. Others</h4>
                            <p><strong>Dipyridamole:</strong> Phosphodiesterase inhibitor. Weak antiplatelet. Used with warfarin for prosthetic valves.</p>

                            <h3>Anticoagulants</h3>
                            <p>Used primarily for venous thrombosis and cardioembolic events.</p>

                            <h4>1. Heparin (Unfractionated)</h4>
                            <p><strong>Mechanism:</strong> Activates Antithrombin III, which inactivates Thrombin (IIa) and Factor Xa. Rapid onset (IV/SC).</p>
                            <p><strong>Monitoring:</strong> aPTT (Activated Partial Thromboplastin Time). Target: 1.5-2.5 times control.</p>
                            <p><strong>Antidote:</strong> Protamine Sulfate (1 mg neutralizes 100 U heparin).</p>
                            <p><strong>Adverse Effects:</strong> Bleeding, Heparin Induced Thrombocytopenia (HIT), Osteoporosis (long term).</p>

                            <h4>2. Low Molecular Weight Heparins (LMWH)</h4>
                            <p><strong>Enoxaparin, Dalteparin.</strong> Selectively inhibit Factor Xa > IIa.</p>
                            <p><strong>Advantages over Unfractionated Heparin:</strong></p>
                            <ul>
                                <li>Better bioavailability (SC).</li>
                                <li>Longer half-life (once/twice daily dosing).</li>
                                <li>Predictable response (no monitoring needed).</li>
                                <li>Lower risk of HIT and bleeding.</li>
                            </ul>

                            <h4>3. Oral Anticoagulants: Warfarin</h4>
                            <p><strong>Mechanism:</strong> Vitamin K antagonist. Inhibits synthesis of factors II, VII, IX, X and Protein C/S. Delayed onset (3-5 days).</p>
                            <p><strong>Monitoring:</strong> PT/INR (Prothrombin Time/International Normalized Ratio). Target INR usually 2-3.</p>
                            <p><strong>Antidote:</strong> Vitamin K1 (Phytonadione), Fresh Frozen Plasma (FFP).</p>
                            <p><strong>Interactions:</strong> Extensive. Enzyme inducers (Rifampicin) decrease effect; Inhibitors (Cimetidine, Metronidazole) increase effect. Antibiotics increase effect (kill gut flora).</p>
                            <p><strong>Contraindications:</strong> Pregnancy (Teratogenic - Fetal Warfarin Syndrome).</p>

                            <h4>4. New Oral Anticoagulants (NOACs)</h4>
                            <ul>
                                <li><strong>Dabigatran:</strong> Direct Thrombin Inhibitor.</li>
                                <li><strong>Rivaroxaban, Apixaban:</strong> Direct Factor Xa Inhibitors.</li>
                            </ul>
                            <p><strong>Advantages:</strong> Fixed dosing, no monitoring, fewer interactions. <strong>Disadvantage:</strong> No specific antidote (historically; Idarucizumab now available for Dabigatran).</p>

                            <h3>Fibrinolytics (Thrombolytics)</h3>
                            <p><strong>Streptokinase, Urokinase, Alteplase (tPA).</strong></p>
                            <p><strong>Mechanism:</strong> Activate Plasminogen to Plasmin, which lyses fibrin clots.</p>
                            <p><strong>Uses:</strong> Acute MI (STEMI within 12h), massive Pulmonary Embolism, acute Ischemic Stroke (within 3-4.5h).</p>
                            <p><strong>Adverse Effects:</strong> Hemorrhage, allergic reactions (Streptokinase).</p>

                            <h3>Antifibrinolytics</h3>
                            <p><strong>Epsilon Aminocaproic Acid (EACA), Tranexamic Acid.</strong> Inhibit plasminogen activation. Used to treat overdose of fibrinolytics, menorrhagia, hemophilia.</p>
                        </div>
                    </section>
                    <!-- END: Chapter 33 -->

                    <!-- START: Chapter 34 -->
                    <section class="content-section" id="chapter-34">
                        <div class="section-header">
                            <div class="section-number">34</div>
                            <h2 class="section-title">
                                <span class="title-icon">üíä</span>
                                Drugs Effective in Iron Deficiency and Other Related Anemias
                            </h2>
                        </div>

                        <div class="content-card">
                            <p><strong>Anemia</strong> is a reduction in hemoglobin concentration below normal for age and sex.</p>

                            <h3>Iron Deficiency Anemia</h3>
                            <p><strong>Iron Metabolism:</strong></p>
                            <ul>
                                <li>Total body iron: 3-5 g.</li>
                                <li>Sources: Heme iron (meat) is better absorbed than non-heme iron (vegetables).</li>
                                <li>Absorption: Duodenum/Jejunum. Enhanced by acid (Vit C), inhibited by phytates/phosphates/tannins.</li>
                                <li>Transport: Transferrin.</li>
                                <li>Storage: Ferritin (soluble), Hemosiderin (insoluble).</li>
                            </ul>

                            <h4>Treatment</h4>
                            <p><strong>1. Oral Iron:</strong> Preferred. <strong>Ferrous sulfate, Ferrous fumarate, Ferrous gluconate</strong>. Dose: 200 mg elemental iron/day.</p>
                            <p><strong>Adverse Effects:</strong> Epigastric pain, nausea, constipation, black stools.</p>
                            
                            <p><strong>2. Parenteral Iron:</strong> Indicated for malabsorption, severe intolerance, non-compliance, rapid correction needed (pregnancy near term).</p>
                            <ul>
                                <li><strong>Iron Dextran:</strong> IM (Z-track) or IV. Risk of anaphylaxis (Test dose required).</li>
                                <li><strong>Iron Sorbitol Citrate:</strong> IM only.</li>
                                <li><strong>Iron Sucrose, Ferric Carboxymaltose:</strong> IV. Safer profile.</li>
                            </ul>

                            <div class="callout callout--danger">
                                <div class="callout-header">
                                    <span class="callout-icon">‚ò¢Ô∏è</span>
                                    <h4 class="callout-title">Acute Iron Poisoning</h4>
                                </div>
                                <div class="callout-content">
                                    <p>Common in children. Symptoms: Necrotizing gastroenteritis, shock, acidosis, liver failure.<br>
                                    <strong>Treatment:</strong> Gastric lavage with bicarbonate. Specific antidote: <strong>Desferrioxamine</strong> (Iron chelator).</p>
                                </div>
                            </div>

                            <h3>Erythropoietin (EPO)</h3>
                            <p>Growth factor produced by kidney. Stimulates RBC proliferation/maturation.</p>
                            <p><strong>Uses:</strong> Anemia of Chronic Renal Failure, Cancer chemotherapy, Zidovudine therapy.</p>
                            <p><strong>Adverse Effects:</strong> Hypertension, thrombotic events.</p>
                        </div>
                    </section>
                    <!-- END: Chapter 34 -->

                    <!-- START: Chapter 35 -->
                    <section class="content-section" id="chapter-35">
                        <div class="section-header">
                            <div class="section-number">35</div>
                            <h2 class="section-title">
                                <span class="title-icon">üß¨</span>
                                Drugs Effective in Megaloblastic Anemias and Neutropenia
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>Vitamin B12 (Cyanocobalamin)</h3>
                            <p>Essential for DNA synthesis (conversion of homocysteine to methionine and methylmalonyl CoA to succinyl CoA). Deficiency causes Megaloblastic Anemia and Neurological damage (Subacute Combined Degeneration).</p>
                            <p><strong>Absorption:</strong> Requires Intrinsic Factor (secreted by gastric parietal cells) for absorption in terminal ileum.</p>
                            <p><strong>Deficiency Causes:</strong> Pernicious anemia (IF deficiency), malabsorption, vegan diet.</p>
                            <p><strong>Treatment:</strong> Parenteral Vitamin B12 (Hydroxycobalamin is preferred - better retention).</p>

                            <h3>Folic Acid</h3>
                            <p>Essential for DNA synthesis (one-carbon transfer reactions). Deficiency causes Megaloblastic Anemia but <strong>NO neurological damage</strong>.</p>
                            <p><strong>Uses:</strong> Megaloblastic anemia (nutritional/pregnancy), Prophylaxis of Neural Tube Defects in fetus (start before conception), Methotrexate toxicity antidote (Folinic acid/Leucovorin).</p>

                            <div class="callout callout--warning">
                                <div class="callout-header">
                                    <span class="callout-icon">‚ö†Ô∏è</span>
                                    <h4 class="callout-title">The "Masking" Effect</h4>
                                </div>
                                <div class="callout-content">
                                    <p>Treating B12 deficiency with Folic acid alone corrects the anemia (hematological picture) but allows neurological damage to progress irreversibly. Always rule out B12 deficiency before treating megaloblastic anemia with folate.</p>
                                </div>
                            </div>

                            <h3>Hematopoietic Growth Factors</h3>
                            <ul>
                                <li><strong>Filgrastim (G-CSF):</strong> Stimulates neutrophil production. Used for neutropenia (chemotherapy-induced, aplastic anemia).</li>
                                <li><strong>Sargramostim (GM-CSF):</strong> Stimulates granulocytes and macrophages.</li>
                                <li><strong>Oprelvekin (IL-11):</strong> Stimulates platelet production (thrombocytopenia).</li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: Chapter 35 -->

                    <!-- START: Chapter 36 -->
                    <section class="content-section" id="chapter-36">
                        <div class="section-header">
                            <div class="section-number">36</div>
                            <h2 class="section-title">
                                <span class="title-icon">‚ö†Ô∏è</span>
                                Drug-Induced Blood Dyscrasias
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Drugs can affect blood cells via direct toxicity or immunological mechanisms.</p>
                            
                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Condition</th>
                                            <th>Implicated Drugs</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>Aplastic Anemia</strong></td>
                                            <td>Chloramphenicol, Cytotoxics, Phenylbutazone, Gold salts, Sulfonamides.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Agranulocytosis</strong></td>
                                            <td>Clozapine, Antithyroids (Carbimazole), Analgin, Sulfonamides, Captopril.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Hemolytic Anemia</strong></td>
                                            <td>G6PD Deficiency: Primaquine, Sulfonamides, Nitrofurantoin.<br>Autoimmune: Methyldopa, Penicillin.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Megaloblastic Anemia</strong></td>
                                            <td>Methotrexate, Phenytoin, Trimethoprim (Folate antagonists).</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Thrombocytopenia</strong></td>
                                            <td>Heparin (HIT), Quinine, Thiazides, Sulfonamides.</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                    </section>
                    <!-- END: Chapter 36 -->
                </main>

                <nav class="document-nav">
                    <div class="nav-container">
                        <a href="section-07.html" class="nav-button nav-button--large nav-button--previous">
                            <div class="nav-label">Previous</div>
                            <div class="nav-title">Section VII: CVS Drugs</div>
                        </a>
                        
                        <div class="document-progress">
                            <div class="progress-indicator">
                                <span>8</span>
                                <span class="progress-separator">/</span>
                                <span>16</span>
                            </div>
                        <a href="../index.html" class="nav-button nav-button--large">
                            <div class="nav-label">Go to</div>
                            <div class="nav-title">Index</div>
                        </a>
                            <div class="progress-bar-container">
                                <div class="progress-bar-fill" style="width: 50%;"></div>
                            </div>
                            <div class="progress-label">Section 8 of 16</div>
                        </div>
                        
                        <a href="section-09.html" class="nav-button nav-button--large nav-button--next">
                            <div class="nav-label">Next</div>
                            <div class="nav-title">Section IX: Renal Drugs</div>
                        </a>
                    </div>
                </nav>
            </article>
        </div>
    </div>

    <!-- Lightbox Modal -->
    <div class="lightbox-modal" id="lightbox-modal" role="dialog" aria-modal="true" aria-label="Image viewer" hidden>
        <div class="lightbox-backdrop"></div>
        <div class="lightbox-content">
            <button class="lightbox-close" aria-label="Close image viewer">√ó</button>
            <img class="lightbox-image" src="" alt="">
            <p class="lightbox-caption"></p>
        </div>
    </div>

    <script src="../js/theme.js"></script>
    <script src="../js/navigation.js"></script>
    <script src="../js/interactions.js"></script>
</body>
</html>